Logo
x

Search

Subscribe Now

Muscular Dystrophy

Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

  • September 2, 2020
Satellos Reports the First Patient Dosing with SAT-3247 in P-I Trial for Duchenne Muscular Dystrophy

    Satellos Reports the First Patient Dosing with SAT-3247 in P-I Trial for Duchenne Muscular Dystrophy

    • September 19, 2024
    Avidity Biosciences Reports the Data from P-I/II (EXPLORE44) Study of Delpacibart Zotadirsen (Del-zota) to Treat Duchenne Muscular Dystrophy

      Avidity Biosciences Reports the Data from P-I/II (EXPLORE44) Study of Delpacibart Zotadirsen (Del-zota) to Treat Duchenne Muscular...

      • August 12, 2024
      Sarepta Therapeutics’ Elevidys Gains the US FDA’s Label Expansion Approval for Duchenne Muscular Dystrophy

        Sarepta Therapeutics’ Elevidys Gains the US FDA’s Label Expansion Approval for Duchenne Muscular Dystrophy

        • June 21, 2024
        Biophytis and Blanver Collaborate to Develop BIO101 for Treating Multiple Indications

          Biophytis and Blanver Collaborate to Develop BIO101 for Treating Multiple Indications

          • June 20, 2024
          Pfizer Reports the P-III Trial Data of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy

            Pfizer Reports the P-III Trial Data of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy

            • June 13, 2024
            Fulcrum Therapeutics Partners with Sanofi to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

              Fulcrum Therapeutics Partners with Sanofi to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

              • May 13, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.